Pharmaceuticals

Recombinant Vaccines Market Advancing with New Opportunities and Industry Developments

April 8, 2026April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Recombinant Vaccines Market Between 2026 And 2030?

The recombinant vaccines market has experienced rapid expansion in recent years. It is projected to increase from $15.79 billion in 2025 to $17.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This past growth is largely due to the effectiveness of hepatitis B recombinant vaccines, established global vaccination initiatives, a greater understanding of viral diseases, increased financial support for immunization, and regulatory backing for more secure vaccine technologies.

The recombinant vaccines market size is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $28.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This growth during the forecast period is primarily driven by factors such as the increasing demand for precision vaccines, the broader development of vaccines for emerging diseases, the rise in adult booster initiatives, an expansion in global immunization coverage, and a robust pipeline of recombinant vaccine candidates. Key trends anticipated during this period encompass a surge in recombinant subunit vaccines, the broadening of vector-based vaccine platforms, more extensive adult immunization campaigns, an increase in combination recombinant vaccines, and an intensified focus on long-lasting immunity.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33287&type=smp

What Key Drivers Are Influencing The Growth Of The Recombinant Vaccines Market?

The escalating prevalence of infectious diseases is set to boost the expansion of the recombinant vaccines market. Such diseases, stemming from germs like bacteria, viruses, fungi, or parasites, are transmissible directly or indirectly among people. This surge in infectious disease prevalence is primarily due to inadequate sanitation and hygiene, where insufficient access to clean water, proper facilities, and effective waste management enables the easy dispersal of harmful microorganisms through tainted food, water, and personal contact, thus elevating infection risks. Recombinant vaccines combat these diseases by utilizing biologically engineered genetic material from pathogens to elicit an immune response without causing sickness. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, over 109,000 chlamydia and more than 40,000 gonorrhea notifications were recorded as the most commonly reported sexually transmitted infections in Australia in 2023, along with more than 6,400 infectious syphilis cases, highlighting the increased incidence and ongoing public health challenges. Consequently, the rising occurrence of infectious diseases is fueling the growth of the recombinant vaccines market.

Which Market Segments Are Examined In The Recombinant Vaccines Market Study?

The recombinant vaccines market covered in this report is segmented –

1) By Type: Subunit Vaccines; Vector-Based Vaccines

2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases

3) By Route Of Administration: Parenteral; Other Route Of Administrations

4) By End User: Pediatric; Adults

Subsegments:

1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines

2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines

Which Trends Are Influencing The Recombinant Vaccines Market?

Leading firms within the recombinant vaccines market are prioritizing the creation of innovative vaccines, particularly the recombinant 9-valent HPV vaccine, to secure a competitive advantage. This recombinant 9-valent HPV vaccine provides protection against nine human papillomavirus (HPV) strains, utilizing recombinant DNA technology for its laboratory production without live viruses, thereby aiding in the prevention of HPV-related conditions like cervical cancer and genital warts. As an illustration, during August 2023, the China-based biopharmaceutical entity Jiangsu Recbio Technology Co. Ltd. progressed REC603, their recombinant 9-valent HPV vaccine, through Phase III clinical follow-up, which included continuing 24-month observations. The vaccine exhibited robust immunogenicity, an advantageous safety profile, capability for scalable manufacturing, and sustained efficacy, reinforcing its promise for extensive HPV prevention and subsequent commercial viability.

Which Companies Hold Significant Positions In The Recombinant Vaccines Market?

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

Read the full recombinant vaccines market report here:

https://www.thebusinessresearchcompany.com/report/recombinant-vaccines-market-report

How Does The Recombinant Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Recombinant Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33287&type=smp

Browse Through More Reports Similar to the Global Recombinant Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Ruminant Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/ruminant-vaccines-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795